Clinical Trials
42 trialsCD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
National Institutes of Health Clinical Center (CC)
MOMENTUM
AstraZeneca
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
CAR-p40-T
Shenzhen University General Hospital
ALLight
AstraZeneca
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Chinese PLA General Hospital
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
PedAL BCU, LLC
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
National Institutes of Health Clinical Center (CC)
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Amgen
Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
St. Jude Children's Research Hospital
CAR-T Cell Therapy Targeting to CD19 for R/R ALL
The First Affiliated Hospital of Soochow University
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Stanford University
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Corporation
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
cAMeLot-1
Janssen Research & Development, LLC
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc.
AUGMENT-101
Syndax Pharmaceuticals
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
University of Chicago
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
Beijing GoBroad Hospital
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
MK-1045-002
MSD R&D (China) Co., Ltd.
ACIT001/EXC002
University of Alberta
TENACITY-01
BIOHENG THERAPEUTICS US LLC
A Study of Revumenib and Mezigdomide in People With Leukemia
Memorial Sloan Kettering Cancer Center
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Fred Hutchinson Cancer Center
CD7-CAR01
Bambino Gesù Hospital and Research Institute
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
Beijing GoBroad Hospital
nanobody CD5
Beijing GoBroad Hospital
HEM-iSMART D
Princess Maxima Center for Pediatric Oncology
HEM-iSMART C
Princess Maxima Center for Pediatric Oncology
HEM-iSMART B
Princess Maxima Center for Pediatric Oncology
CLIC-01
Ottawa Hospital Research Institute
BAH241
Essen Biotech
CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study
Zhujiang Hospital
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Chinese PLA General Hospital
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
Case Comprehensive Cancer Center
PTCy and ATG for MSD and MUD Transplants
Instituto Nacional de Cancer, Brazil
CARTHEDRALL
University of Sao Paulo
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
University Hospital Heidelberg
CAPTiRALL
Assistance Publique - Hôpitaux de Paris
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Shenzhen TargetRx Co., Ltd.